e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Models of airways disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Protective effect of a Protein Epitope Mimetic (PEM) CXCR4 antagonist, POL5551, in an allergic model of asthma
F. Daubeuf, B. Romagnoli, E. Chevalier, N. Frossard (Illkirch, France; Allschwil, Switzerland)
Source:
Annual Congress 2010 - Models of airways disease
Session:
Models of airways disease
Session type:
E-Communication Session
Number:
3704
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Daubeuf, B. Romagnoli, E. Chevalier, N. Frossard (Illkirch, France; Allschwil, Switzerland). Protective effect of a Protein Epitope Mimetic (PEM) CXCR4 antagonist, POL5551, in an allergic model of asthma. Eur Respir J 2010; 36: Suppl. 54, 3704
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Protective effect of a protein epitope mimetic (PEM) CCR10 antagonist, POL7085, in an allergic model of asthma
Source: Annual Congress 2011 - Translational models of airway disease
Year: 2011
Protective effect of thrombomodulin in a murine model of allergen-induced asthma
Source: Annual Congress 2010 - Animal models of asthma and lung inflammation
Year: 2010
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459
Source: Eur Respir J 2013; 41: 46-52
Year: 2013
Alpha-7 nicotinic receptor stimulation reduces airway inflammation in a murine model of asthma
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists
Source: Annual Congress 2013 –The pulmonary epithelium: recent developments
Year: 2013
The effect of anti-IL-33 antibody and soluble ST2 in a murine model of allergic asthma
Source: Annual Congress 2013 –Murine models of lung immunology
Year: 2013
Resveratrol upregalates PTEN and inhibits MUC5AC expression in ovalbumin (OVA)-induced asthma model mice
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Effects of the novel toll-like receptor 7 (TLR7) agonist AZD8848 on allergen-induced responses in patients with mild asthma
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012
Effect of retinoid X receptor partial agonist on airway inflammation and hyperresponsiveness
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014
Late Breaking Abstract - The Role of the chemokine receptor CCR3 in House Dust Mite (HDM) induced experimental asthma
Source: Virtual Congress 2020 – New insight into the immunology of asthma and COPD
Year: 2020
TLR 7/8 agonist resiquimod alleviates murine allergic asthma through IL-27 production and up regulation of B7-H1 on antigen presenting cells
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015
Exploring the role of Coxsackie and Adenovirus Receptor (CAR) in allergic airway inflammation
Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses
Year: 2019
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Acid sphingomyelinase deficiency improves lung function in allergen-induced asthma in mice
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Cytokine-induced glucocorticoid resistance: Effect on GILZ expression and reversal by formoterol
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept